Two more drug-making giants, Abbvie and Genentech, will start selling popular medications on the White House's discounted pharmaceutical site as soon as Monday.

Pharmaceutical companies AbbVie (NYSE:ABBV) and Pfizer (NYSE:PFE) both reported fourth-quarter earnings in early February, ...

Prescriptions for an adalimumab biosimilar among new users rose from 0% to 24% after CVS Caremark added it to its formulary, ...

AbbVie ABBV is set to report first-quarter 2026 results on April 29, with investor focus likely to remain on its immunology ...

Adalimumab is a medication used to treat rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, ulcerative colitis, chronic psoriasis, hidradenitis suppurativa, and ...

This year, CVS Health plans to employ the classic "out with the old, in with the new" mantra when it comes to AbbVie’s Humira. Come April 1, the branded drug will be replaced by cheaper biosimilars ...

(Reuters) - Cigna said on Monday it will remove AbbVie’s blockbuster rheumatoid arthritis drug Humira from some of its lists of preferred drugs for reimbursement in 2025, and recommend less pricey ...

Add Yahoo as a preferred source to see more of our stories on Google. North Chicago-based drugmaker AbbVie must pay back Medicare for raising the price of its blockbuster drug Humira too quickly, the ...

AbbVie’s ABBV rheumatoid arthritis drug Humira, one of the top-selling biopharmaceutical products of all time, will have new lower-cost competition starting Saturday. But even as nearly identical ...

Forbes contributors publish independent expert analyses and insights. Joshua Cohen is a Boston-based writer who covers health policy. In a unique challenge to drug makers, the Dutch Pharmaceutical ...

Just about every Medicare Part D prescription drug plan on offer this year covers the original version of adalimumab (Humira), whereas only about half will pay for any of the several biosimilar ...